"Neurocrine Biosciences ( NASDAQ: NBIX) delivered a decisive earnings beat in Q3, posting adjusted EPS of $2.17 against expectations of $1.62 and revenue of $794.9M versus $761.4M consensus. The 34% EPS outperformance and 4.4% revenue beat reflect accelerating demand for its core neuroscience franchises. The stock pulled back 1.05% today to $147.38, a modest retreat after yesterday's 3.4% surge that had pushed shares to 3-month highs near $150."
"INGREZZA, Neurocrine's flagship involuntary movement disorder treatment, generated $687M in sales, up 12% year over year. This steady growth underscores persistent patient demand and successful market penetration in a category where competitive pressure has intensified. Total net product sales reached $790M, up 28% YoY, driven largely by INGREZZA's consistency and the emerging contribution from CRENESSITY, the company's newer offering for tardive dyskinesia that posted $98M in its first full quarter of meaningful sales."
"Leadership emphasized the clinical trajectory ahead. CEO Kyle W. Gano noted that Neurocrine is "well positioned to lead the next wave of innovation in neuroscience," pointing to registration-enabling trials now enrolling for osavampator in major depressive disorder and a second Phase 3 trial initiated for direclidine in schizophrenia. The company presented Phase 2 SAVITRI study data for osavampator, adding clinical validation to near-term catalysts."
Neurocrine Biosciences posted Q3 adjusted EPS of $2.17 versus $1.62 expected and revenue of $794.9M versus $761.4M consensus, representing a 34% EPS outperformance and a 4.4% revenue beat. INGREZZA generated $687M in sales, up 12% year over year, while total net product sales reached $790M, up 28% YoY, aided by CRENESSITY's $98M in its first full quarter. Non-GAAP net income rose to $222M from $189M, and GAAP net income was $209.5M. The company reaffirmed full-year INGREZZA guidance of $2.5B–$2.55B. Registration-enabling trials for osavampator and a Phase 3 for direclidine are underway, with Phase 2 SAVITRI data presented.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]